During the last session, Enliven Therapeutics Inc (NASDAQ:ELVN)’s traded shares were 0.51 million, with the beta value of the company hitting 1.02. At the end of the trading day, the stock’s price was $21.86, reflecting an intraday loss of -0.82% or -$0.18. The 52-week high for the ELVN share is $30.03, that puts it down -37.37 from that peak though still a striking 50.14% gain since the share price plummeted to a 52-week low of $10.90. The company’s market capitalization is $1.07B, and the average intraday trading volume over the past 10 days was 0.28 million shares, and the average trade volume was 223.32K shares over the past three months.
Enliven Therapeutics Inc (NASDAQ:ELVN) trade information
Enliven Therapeutics Inc (ELVN) registered a -0.82% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.82% in intraday trading to $21.86, hitting a weekly high. The stock’s 5-day price performance is -0.59%, and it has moved by -2.71% in 30 days. Based on these gigs, the overall price performance for the year is 44.67%. The short interest in Enliven Therapeutics Inc (NASDAQ:ELVN) is 6.93 million shares and it means that shorts have 36.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $39.5, which implies an increase of 44.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $39 and $40 respectively. As a result, ELVN is trading at a discount of -82.98% off the target high and -78.41% off the low.
Enliven Therapeutics Inc (ELVN) estimates and forecasts
Statistics show that Enliven Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Enliven Therapeutics Inc (ELVN) shares have gone down -8.95% during the last six months, with a year-to-date growth rate less than the industry average at 2.99% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.16%. While earnings are projected to return 5.14% in 2025, the next five years will return -9.63% per annum.
ELVN Dividends
Enliven Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Enliven Therapeutics Inc (NASDAQ:ELVN)’s Major holders
Enliven Therapeutics Inc insiders own 6.39% of total outstanding shares while institutional holders control 98.75%, with the float percentage being 105.49%.
Also, the Mutual Funds coming in first place with the largest holdings of Enliven Therapeutics Inc (ELVN) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.08 shares. This amounts to just over 2.21 percent of the company’s overall shares, with a $23.57 million market value. The same data shows that the other fund manager holds slightly less at 905.62, or about 1.85% of the stock, which is worth about $19.8 million.
